TICKERNERD
Menu
AIMAIMHealthcare · Biotechnology

AIM Stock Forecast: AIM ImmunoTech, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$0.18
−0.22% on the day

The 2 Wall Street analysts covering AIM ImmunoTech, Inc. hold a median 12-month price target of $4.25 — +2266.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 19 of 100 as at 8 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$7.2M
Ticker Nerd rank
19 / 100
Median analyst target
$4.25
Analysts covering
2
Revenue$22K+37.5% y/y
Operating income−$2.2M
Net income−$3.0M
Free cash flow−$2.8M
Quarterly, 7 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.5%
1M
−21.9%
YTD
−83.6%
1Y
−92.8%
From 52W high
−93.3%
From 52W low
+5.6%
$0.17
$2.68
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AIM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores AIM ImmunoTech, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
19 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
94
Revisions
67
Growth
55
Accruals
26
Momentum
25
Value
15
Volatility
11
Quality
7
Issuance
5

Size (94): Smaller than most of the companies we track.

Issuance (5): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AIM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AIM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00Jan 26Apr 26Jul 26Oct 26AIMHigh $7.00Median $4.25Low $1.50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $1.50Median $4.25High $7.00

The green dot is the last close — the median target sits +2266.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
20 Aug 2026Ascendiant CapitalMaintainsBuy—
1 June 2026Ascendiant CapitalMaintainsBuy—
10 Apr 2026Ascendiant CapitalMaintainsBuy—
8 Dec 2025Ascendiant CapitalMaintainsBuy—
3 Oct 2025Ascendiant CapitalMaintainsBuy—
10 Dec 2024Ascendiant CapitalMaintainsBuy—
22 Oct 2024Maxim GroupMaintainsBuy—
3 Sept 2024Ascendiant CapitalMaintainsBuy—
10 Oct 2019Maxim GroupUpgradeBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AIM appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

AIM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, AIM ImmunoTech, Inc. returned −92.8% against +16.2% for the S&P 500, dividends included.

AIM vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26AIMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AIM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

AIM ImmunoTech, Inc. (AIM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.0×

Cheaper than 76% of US stocks

Price / sales
78.3×

Cheaper than 4% of US stocks

Price / book
0.7×

Cheaper than 80% of US stocks

EV / EBITDA
0.0×

Cheaper than 61% of US stocks

Growth & margins
Revenue growth (YoY)
4.0%

Higher than 36% of US stocks

Earnings growth (YoY)
37.5%

Higher than 70% of US stocks

Gross margin
81.8%

Higher than 92% of US stocks

Operating margin
−13511.5%

Higher than 2% of US stocks

Net margin
−45.5%

Higher than 11% of US stocks

Returns & dividend
Return on equity
−2382.3%

Higher than 1% of US stocks

Return on assets
−82.6%

Higher than 4% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

AIM ImmunoTech, Inc. (AIM) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • AIM ImmunoTech, Inc. has a market value of $7.2M and an enterprise value of −$487K.

  • Revenue in the twelve months to 31 Mar 2026: $94K. The latest quarter grew 4.0% year on year.

  • Net income over the same four quarters: −$13.3M, a −14123.4% net margin.

  • Free cash flow in the twelve months to 31 Mar 2026: −$11.7M.

  • Shares outstanding: 39.9M.

  • Trailing P/E: −0.0×; forward P/E: −0.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • AIM ImmunoTech, Inc. employs 19 people — $5K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

AIM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
AIMAIM ImmunoTech, Inc.$7.2M
19
BOLTBolt Biotherapeutics, Inc.$7.0M
78
ACXPAcurx Pharmaceuticals, Inc.$6.9M
22
APREAprea Therapeutics, Inc.$6.9M
45
TRAWTraws Pharma, Inc.$7.3M
43
ENVBEnveric Biosciences, Inc.$6.8M
21
NRSNNeurosense Therapeutics Ltd.$6.8M
3

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own AIM ImmunoTech, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AIM news & analysis

AIM ImmunoTech's Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays

GlobeNewsWire · 7 Oct 2026positive

A BioTuesdays CEO interview featured AIM ImmunoTech’s strategy to address immune resistance in pancreatic cancer. The discussion explored Ampligen’s potential to extend survival and improve quality of life as the company advances toward pivotal development.

Why it matters — The interview highlights AIM’s stated development focus for Ampligen in pancreatic cancer and the potential outcomes being explored.

AIM ImmunoTech Highlights Recent Media Coverage of Ampligen's® Broad-Spectrum Antiviral and Biodefense Potential

GlobeNewsWire · 5 Oct 2026neutral

AIM ImmunoTech announced it is highlighting recent media coverage of the antiviral and biodefense potential of Ampligen, its investigational dsRNA and selective TLR3 agonist immunomodulator.

Why it matters — AIM watchers would care because the company is drawing attention to Ampligen's broad-spectrum antiviral potential, which could raise visibility for its investigational candidate.

AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data

GlobeNewsWire · 1 Oct 2026positive

Biotech media coverage has recently highlighted Ampligen's potential to address immune resistance in metastatic pancreatic cancer, alongside the clinical progress of the Phase 2 DURIPANC program as it advances toward topline data.

Why it matters — AIM watchers would care because this reflects growing external attention on Ampligen's pancreatic cancer strategy and the DURIPANC program as it moves toward topline results.

AIM ImmunoTech Discusses Ampligen®'s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video

GlobeNewsWire · 30 Sept 2026positive

AIM ImmunoTech released a new CEO Corner video discussing Ampligen's potential to complement emerging pancreatic cancer therapies, highlighting supportive survival observations, biomarker-driven patient selection, and upcoming Phase 2 DURIPANC milestones.

Why it matters — The update signals potential progress in AIM's pancreatic cancer development program with upcoming Phase 2 DURIPANC milestones that could affect the company's valuation.

AIM ImmunoTech Highlights Ampligen's Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines' Daraxonrasib

GlobeNewsWire · 22 Sept 2026positive

AIM ImmunoTech issued a letter to stockholders from CEO Thomas Equels following the FDA's approval of Revolution Medicines' daraxonrasib, outlining Ampligen's differentiated mechanism, clinical profile, and potential role in pancreatic cancer treatment. The company highlighted survival data showing Ampligen-associated median overall survival of 34.8 months in a selected pancreatic patient population versus 12.5 months in historical controls.

Why it matters — AIM watchers would care because the letter affirms Ampligen's potential place in the evolving pancreatic cancer treatment landscape and draws attention to its reported survival data.

FAQ

Frequently asked questions about AIM stock

What is the AIM stock price forecast for 2026-2027?

The 2 Wall Street analysts covering AIM ImmunoTech, Inc. have a median 12-month price target of $4.25, with estimates ranging from $1.5 to $7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AIM stock a buy right now?

Of the 2 analysts covering AIM ImmunoTech, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks AIM ImmunoTech, Inc. 19 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AIM?

As at 8 Oct 2026, AIM ImmunoTech, Inc. ranks 19 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).

Will AIM stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +2266.4% from the last close, and Ticker Nerd's factor model ranks AIM ImmunoTech, Inc. 19 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AIM stock forecast for 2030?

No analyst covering AIM ImmunoTech, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AIM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.5 to $7 over the next 12 months.

How has AIM stock performed over the past year?

AIM ImmunoTech, Inc. returned -92.8% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does AIM ImmunoTech, Inc. do?

AIM ImmunoTech Inc. is a biotechnology company focused on developing immuno-modulating therapeutics for cancer, viral diseases, and immune-related disorders.

What is the latest news on AIM?

The most recent item we track (GlobeNewsWire, 7 Oct 2026): "AIM ImmunoTech's Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays". A BioTuesdays CEO interview featured AIM ImmunoTech’s strategy to address immune resistance in pancreatic cancer. The discussion explored Ampligen’s potential to extend survival and improve quality of life as the company advances toward pivotal development.

Company

About AIM ImmunoTech, Inc.

AIM ImmunoTech Inc. is a biotechnology company focused on developing immuno-modulating therapeutics for cancer, viral diseases, and immune-related disorders. Its current portfolio centers on Ampligen, an investigational double-stranded RNA therapy being evaluated in clinical studies for oncology and selected viral and immune conditions, and Alferon N Injection, a natural-source interferon product used for specific approved indications. The company works across preclinical and clinical research, with an emphasis on immune system activation, antiviral defense, and combination approaches for difficult-to-treat diseases. AIM ImmunoTech serves the biopharmaceutical sector by advancing specialized therapies that target areas with limited treatment options, making it a recognized participant in immunotherapy and antiviral drug development.

CEO Mr. Thomas K. Equels Esq., J.D., M.S. · 19 employees · United States · https://aimimmuno.com